Lummy(SZ:300006) Cai Jing Wang·2025-10-22 05:58Core Viewpoint - Recently, the company reported a decline in revenue and incurred losses for the first three quarters of 2025, indicating challenges in its financial performance [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 581 million, a year-on-year decrease of 4.1% [1] - The net profit attributable to the parent company was a loss of 45.92 million [1] - In the third quarter, the operating revenue was 204 million, reflecting a year-on-year decline of 8.9% [1] - The net profit attributable to the parent company for the third quarter was a loss of 14.54 million [1] Regulatory Approvals - During the reporting period, the company received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (specification: 0.5g) and obtained drug registration certificates for Nicorandil tablets (specification: 5mg) and Ketorolac Tromethamine injection (specification: 1ml: 30mg) [1] Shareholding Changes - On September 26, 2025, the company was notified by its controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group"), about a capital increase agreement and share transfer agreement signed by its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (hereinafter referred to as "Guangxi Investment Group") [1] - Guangxi Investment Group plans to increase capital in Guangxi Investment Group Financial Holdings Co., Ltd. (hereinafter referred to as "Guangxi Financial Holdings") by transferring 859,343,587 shares of Zhongheng Group [1] - After the completion of this transaction, Guangxi Financial Holdings will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will continue to be the actual controller of the company [1]